Laboratory Assessment of the Anticoagulant Activity of Direct Oral Anticoagulants: A Systematic Review

摘要

The development of an oral thrombin inhibitor (dabigatran) and oral factor Xa inhibitors (rivaroxaban, apixaban, and edoxaban) has changed the management of anticoagulation in patients with nonvalvular atrial fibrillation (AF) and VTE. As of January 2016, the American College of Chest Physicians (CHEST) and other organizations recommended these drugs over vitamin K antagonists as the agents of choice for management of noncancer-associated VTE.